Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
F&G: 63
6.007,45 S&P · 18,60 Vola-Index · 104.608,21 BTC · 1,13992 EURUSD
Systemstatus: 46.644 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US7613301099
Letzte Aktualisierung: 06.06.2025 | 6PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG00BCQ64N4
RVNC
Revance Therapeutics, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
NAME
Revance Therapeutics, Inc.
ISIN
US7613301099
TICKER
RVNC
MIC
XNAS
REUTERS
RVNC.OQ
BLOOMBERG
RVNC US
Fr., 28.02.2025       Revance Therapeutics
US7613301099

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024. Revance describes itself as a “biotechnology company that develops, manufactures, and commercializes neuromodulators ...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 28.02.2025       Revance Therapeutics
US7613301099

The law firm of Kirby McInerney LLP alerts investors of the imminent March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities between February 29, 2024, through December 6, 2024 (“the Class P...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 19.02.2025       Revance Therapeutics
US7613301099

Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as l...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 07.02.2025       Revance Therapeutics
US7613301099

Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aestheti...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 21.01.2025       Revance Therapeutics
US7613301099

Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance”), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the “Second Amendment,” together with the Amended and Restated Merger Agreement, dated December 7, 2024, the “A&R Merger Agreemen...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
So., 19.01.2025       Revance Therapeutics
US7613301099

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for a...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 10.01.2025       Revance Therapeutics
US7613301099

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for a...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 10.01.2025       Revance Therapeutics
US7613301099

Glancy Prongay & Murray LLP reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (th...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 08.01.2025       Revance Therapeutics
US7613301099

Law Offices of Howard G. Smith reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). IF YOU ARE...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 08.01.2025       Revance Therapeutics
US7613301099

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 07.01.2025       Revance Therapeutics
US7613301099

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). Revance investors have until March 4, 2025 to file a lead plaint...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 07.01.2025       Revance Therapeutics
US7613301099

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mo., 06.01.2025       Revance Therapeutics
US7613301099

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). Revance investors have until March 4, 2025 to file a lead plaintif...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 17.12.2024       Revance Therapeutics
US7613301099

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Revance Therapeutics, Inc. (NasdaqGM: RVNC) to Crown Laboratories, Inc. Under the terms of the proposed transaction, shareholders of Revance will receive $3.10 in cash for each share of Revan...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Do., 12.12.2024       Revance Therapeutics
US7613301099

Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the r...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mo., 09.12.2024       Revance Therapeutics
US7613301099

Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merg...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Do., 07.11.2024       Revance Therapeutics
US7613301099

Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance,” the “Company” or “our”), today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. Third Quarter Highlights and Subsequent Updates Crown Laboratories and Revance Announce Entry Into Merger Agreement and Delay of Tender Offer Commencement...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Do., 17.10.2024       Revance Therapeutics
US7613301099

The Law Offices of Frank R. Cruz announces an investigation of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 23, 2024, Revance disclosed in ...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 16.10.2024       Revance Therapeutics
US7613301099

Law Offices of Howard G. Smith announces an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company’s possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 16.10.2024       Revance Therapeutics
US7613301099

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Re...
weiterlesen
Revance Therapeutics
Research & Analysen Termsheet Terminal
Permalink

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds